CD19 UCAR-T cells for autoimmune diseases
Part of Blood & lymphatic, Bones, joints & muscles, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- Your organs (like heart, lungs, liver, kidneys) must be working well enough.
- You must have one of these autoimmune diseases that's active and hasn't responded to standard treatments: lupus, scleroderma, inflammatory myositis, vasculitis, Sjögren's syndrome, antiphospholipid syndrome, or immune thrombocytopenia.
- If you have lupus, you need a certain level of disease activity and have tried standard therapy for at least 6 months with no success.
- If you have scleroderma, your lung function must be adequate, and your disease must have come back or not responded to treatment.
- You cannot have had certain other treatments recently, like B-cell-depleting therapies, high-dose steroids, or other experimental drugs.
- You cannot have other serious medical conditions such as active cancer, severe infections, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This trial tests a new treatment using UCAR T-cells that target CD19 and BCMA proteins, for people with autoimmune diseases like lupus or arthritis that have come back or not responded to other treatments. It aims to see if this therapy can help control the disease.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.